New drug targets obesity in early human trials
NCT ID NCT06700538
Summary
This early-stage study is testing a new drug called ARO-INHBE for adults with obesity, including some who also have type 2 diabetes. Researchers want to see if the drug is safe and how it affects the body, particularly when taken alongside another weight-loss medication. The study will enroll 120 participants to test different doses and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGGrafton, Auckland, 1010, New Zealand
-
Research Site 2
RECRUITINGChristchurch, 8011, New Zealand
-
Research Site 3
RECRUITINGAuckland, 2025, New Zealand
Conditions
Explore the condition pages connected to this study.